Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine ...

AbbVie (ABBV) shares snapped eight consecutive sessions of losses as the stock closed up XYZ% at $XYZ. The North ...

Last year, pharmaceutical giant AbbVie (NYSE: ABBV) lost patent exclusivity for its biggest cash cow, immunology medicine ...

The company has a one-year high of $207.32 and a one-year low of $137.14. Currently, AbbVie has an average volume of 5.31M. TipRanks tracks over 100,000 company insiders, identifying the select few ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of AbbVie (NYSE:ABBV) with a Outperform ...

Dividend stocks are attractive for their steady income, stability, and growth potential, especially amid low interest rates ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

The market’s momentum is fueled by a concerted effort towards the development of innovative treatments for hematologic malignancies. Advances in drug discovery, coupled with regulatory approvals for ...

Real-time index price for TSX American Preferred Stock Index (STNC), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

Even if emraclidine is not a complete write-off, this sets back AbbVie's muscarinic pipeline by at least several years, ...

AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...